Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?
Biosci Trends
; 14(6): 467-468, 2021 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1006049
ABSTRACT
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that struck in late 2019 and early 2020 is a serious threat to human health. Since there are no approved drugs that satisfactorily treat this condition, all efforts at drug design and/or clinical trials are warranted and reasonable. Drug repurposing is a well-known strategy that seeks to deploy existing licensed drugs for newer indications and that provides the quickest possible transition from the bench to the bedside to meet therapeutic needs. At present, several existing licensed drugs such as chloroquine, hydroxychloroquine, methylprednisolone, dexamethasone, and remdesivir have been used because of their potential efficacy in inhibiting COVID-19. Recently, antibiotics such as tetracyclines and macrolides have been reported to be effective against COVID-19. A combination of tetracyclines and macrolides may be a potential treatment for COVID-19 because there are some differences in the mechanism of action of tetracyclines and macrolides.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Tetraciclina
/
Macrólidos
/
Tratamiento Farmacológico de COVID-19
/
Antibacterianos
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Biosci Trends
Asunto de la revista:
Biologia
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Bst.2020.03443
Similares
MEDLINE
...
LILACS
LIS